Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLD131
MIFTS: 62

Bladder Urothelial Carcinoma

Categories: Cancer diseases, Nephrological diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bladder Urothelial Carcinoma

About this section

MalaCards integrated aliases for Bladder Urothelial Carcinoma:

Name: Bladder Urothelial Carcinoma 12 15
Transitional Cell Carcinoma of the Bladder 29 6
Transitional Cell Carcinoma of Bladder 12 73
Urinary Bladder Urothelial Carcinoma 12
Bladder Transitional Cell Carcinoma 12
Carcinoma Transitional Cell Bladder 55
Urothelial Bladder Carcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4006
NCIt 50 C39851
UMLS 73 C0279680
Sources

Summaries for Bladder Urothelial Carcinoma

About this section
Disease Ontology : 12 A bladder carcinoma that has material basis in transitional cells located in the lining of the bladder.

MalaCards based summary : Bladder Urothelial Carcinoma, also known as transitional cell carcinoma of the bladder, is related to transitional cell carcinoma and adenoma. An important gene associated with Bladder Urothelial Carcinoma is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Gemcitabine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include prostate, lymph node and testes, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Bladder Urothelial Carcinoma

About this section

Diseases related to Bladder Urothelial Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 289)
# Related Disease Score Top Affiliating Genes
1 transitional cell carcinoma 31.9 BRAF ERBB2 FGFR3 HRAS TP53
2 adenoma 30.4 BRAF CTNNB1 KRAS TP53
3 undifferentiated pleomorphic sarcoma 30.2 IDH1 KRAS PIK3CA
4 nevus, epidermal 30.2 FGFR3 HRAS KRAS NRAS PIK3CA
5 suppression of tumorigenicity 12 30.0 AKT1 BRAF CTNNB1 HRAS IDH1 PIK3CA
6 retinoblastoma 29.9 HOTAIR MALAT1 MEG3 TP53
7 renal cell carcinoma, nonpapillary 29.8 GAS5 HOTAIR MALAT1 PVT1 TUG1
8 adenocarcinoma 29.6 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
9 squamous cell carcinoma 29.5 AKT1 BRAF CTNNB1 ERBB2 FGFR3 HOTAIR
10 bladder cancer 29.3 ERBB2 FGFR3 GAS5 HOTAIR HRAS KRAS
11 melanoma 28.9 BRAF GAS5 HOTAIR MALAT1 MAP2K1 MEG3
12 prostate cancer 28.8 AKT1 CTNNB1 ERBB2 FGFR1 GAS5 HOTAIR
13 lung cancer 28.3 AKT1 BRAF ERBB2 FGFR1 FGFR3 GAS5
14 non-papillary transitional cell carcinoma of the bladder 12.6
15 infiltrating bladder urothelial carcinoma sarcomatoid variant 12.4
16 clear cell variant infiltrating bladder urothelial carcinoma 12.3
17 non-invasive bladder urothelial carcinoma 12.3
18 micropapillary variant infiltrating bladder urothelial carcinoma 12.3
19 lipid-cell variant infiltrating bladder urothelial carcinoma 12.3
20 plasmacytoid variant infiltrating bladder urothelial carcinoma 12.3
21 nested variant infiltrating bladder urothelial carcinoma 12.3
22 microcystic variant infiltrating bladder urothelial carcinoma 12.3
23 lymphoma-like variant infiltrating bladder urothelial carcinoma 12.3
24 invasive bladder transitional cell carcinoma 11.4
25 small cell carcinoma of the bladder 11.4
26 malignant spiradenoma 10.5 PIK3CA TP53
27 non-invasive bladder papillary urothelial neoplasm 10.5 FGFR3 TP53
28 dermatosis papulosa nigra 10.5 FGFR3 PIK3CA
29 actinic cheilitis 10.5 FGFR3 TP53
30 gastric papillary adenocarcinoma 10.4 ERBB2 TP53
31 prostate transitional cell carcinoma 10.4 CTNNB1 PIK3CA
32 anal squamous cell carcinoma 10.4 AKT1 PIK3CA TP53
33 prostate adenoid cystic carcinoma 10.4 HRAS PIK3CA
34 male reproductive organ cancer 10.4 AKT1 CTNNB1 TP53
35 ductal carcinoma in situ 10.4 AKT1 ERBB2 TP53
36 gonadal disease 10.4 AKT1 ERBB2 TP53
37 plagiocephaly 10.4 FGFR1 FGFR3
38 hepatoblastoma 10.4 CTNNB1 TP53 TUG1
39 cerebellar astrocytoma 10.4 IDH1 TP53
40 intracranial chondrosarcoma 10.4 IDH1 TP53
41 oral cavity cancer 10.4 ERBB2 PIK3CA TP53
42 epidermolytic nevus 10.4 FGFR3 NRAS
43 peripheral nervous system neoplasm 10.4 AKT1 NRAS TP53
44 splenic diffuse red pulp small b-cell lymphoma 10.4 MAP2K1 TP53
45 nervous system cancer 10.4 AKT1 IDH1 TP53
46 central nervous system cancer 10.4 AKT1 IDH1 TP53
47 adult hepatocellular carcinoma 10.4 CTNNB1 PIK3CA TP53
48 rare adenocarcinoma of the breast 10.4 AKT1 KRAS PIK3CA TP53
49 uterine corpus serous adenocarcinoma 10.4 ERBB2 PIK3CA TP53
50 breast squamous cell carcinoma 10.3 ERBB2 PIK3CA TP53

Graphical network of the top 20 diseases related to Bladder Urothelial Carcinoma:



Diseases related to Bladder Urothelial Carcinoma
Sources

Symptoms & Phenotypes for Bladder Urothelial Carcinoma

About this section

GenomeRNAi Phenotypes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

26 (show top 50) (show all 59)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.89 BRAF HRAS KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.89 KRAS
3 Decreased viability GR00107-A-1 10.89 MAP2K1
4 Decreased viability GR00221-A-1 10.89 HRAS KRAS PIK3CA AKT1 FGFR1 FGFR3
5 Decreased viability GR00221-A-2 10.89 HRAS KRAS PIK3CA AKT1 FGFR1 FGFR3
6 Decreased viability GR00221-A-3 10.89 HRAS AKT1 FGFR3 ERBB2 MAP2K1 NRAS
7 Decreased viability GR00221-A-4 10.89 BRAF PIK3CA AKT1 ERBB2
8 Decreased viability GR00301-A 10.89 BRAF KRAS
9 Decreased viability GR00342-S-1 10.89 MAP2K1
10 Decreased viability GR00342-S-2 10.89 MAP2K1
11 Decreased viability GR00342-S-3 10.89 MAP2K1
12 Decreased viability GR00381-A-1 10.89 BRAF KRAS
13 Decreased viability GR00402-S-2 10.89 BRAF HRAS KRAS PIK3CA AKT1 FGFR1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.22 FGFR1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.22 CTNNB1 KRAS
16 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.22 BRAF
17 Increased shRNA abundance (Z-score > 2) GR00366-A-113 10.22 CTNNB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.22 KRAS
19 Increased shRNA abundance (Z-score > 2) GR00366-A-125 10.22 FGFR1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.22 FGFR1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.22 IDH1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.22 IDH1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.22 IDH1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.22 IDH1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.22 BRAF
26 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.22 PIK3CA
27 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.22 AKT1 PIK3CA
28 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.22 BRAF PIK3CA
29 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.22 KRAS
30 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.22 FGFR1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.22 IDH1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.22 AKT1 BRAF CTNNB1 KRAS PIK3CA
33 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.22 FGFR1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.22 PIK3CA
35 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.22 BRAF
36 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.22 KRAS
37 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.22 CTNNB1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.22 KRAS
39 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.22 BRAF
40 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.22 BRAF
41 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.22 BRAF
42 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.22 IDH1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.22 AKT1 PIK3CA
44 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.22 FGFR1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.22 BRAF CTNNB1 FGFR1 IDH1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.22 CTNNB1 KRAS PIK3CA
47 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.22 AKT1 KRAS FGFR1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.22 KRAS
49 Increased shRNA abundance (Z-score > 2) GR00366-A-67 10.22 CTNNB1
50 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.22 AKT1

MGI Mouse Phenotypes related to Bladder Urothelial Carcinoma:

46 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.43 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
2 behavior/neurological MP:0005386 10.41 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
3 homeostasis/metabolism MP:0005376 10.41 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
4 cardiovascular system MP:0005385 10.4 AKT1 BRAF CTNNB1 ERBB2 FGFR1 HRAS
5 cellular MP:0005384 10.4 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
6 integument MP:0010771 10.36 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
7 mortality/aging MP:0010768 10.36 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
8 craniofacial MP:0005382 10.35 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
9 digestive/alimentary MP:0005381 10.35 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
10 embryo MP:0005380 10.34 AKT1 BRAF CTNNB1 ERBB2 FGFR1 KRAS
11 endocrine/exocrine gland MP:0005379 10.33 AKT1 BRAF CTNNB1 ERBB2 FGFR1 HRAS
12 immune system MP:0005387 10.3 AKT1 BRAF CTNNB1 FGFR1 FGFR3 IDH1
13 neoplasm MP:0002006 10.26 AKT1 BRAF CTNNB1 ERBB2 FGFR3 HRAS
14 nervous system MP:0003631 10.23 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
15 normal MP:0002873 10.18 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
16 limbs/digits/tail MP:0005371 10.14 BRAF CTNNB1 ERBB2 FGFR1 FGFR3 KRAS
17 hearing/vestibular/ear MP:0005377 10.12 BRAF CTNNB1 FGFR1 FGFR3 KRAS MAP2K1
18 muscle MP:0005369 10.1 AKT1 BRAF CTNNB1 ERBB2 FGFR1 KRAS
19 liver/biliary system MP:0005370 10.07 AKT1 BRAF CTNNB1 KRAS NFE2L2 NRAS
20 no phenotypic analysis MP:0003012 10.03 CTNNB1 FGFR1 FGFR3 HRAS KRAS NRAS
21 reproductive system MP:0005389 9.96 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
22 renal/urinary system MP:0005367 9.92 BRAF CTNNB1 FGFR1 FGFR3 HRAS KRAS
23 respiratory system MP:0005388 9.85 AKT1 BRAF CTNNB1 ERBB2 FGFR3 HRAS
24 skeleton MP:0005390 9.8 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
25 pigmentation MP:0001186 9.77 BRAF CTNNB1 KRAS NRAS TP53
26 vision/eye MP:0005391 9.28 BRAF CTNNB1 FGFR1 FGFR3 KRAS MAP2K1
Sources

Drugs & Therapeutics for Bladder Urothelial Carcinoma

About this section

Drugs for Bladder Urothelial Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
2
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
3
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 5280965 14956
4
Tocopherol Approved, Investigational Phase 3 1406-66-2 14986
5
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
6
Valrubicin Approved Phase 3,Phase 2 56124-62-0 41744
7
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
8
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
9
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
10
Nicotinamide Approved, Investigational Phase 3,Phase 2 98-92-0 936
11
leucovorin Approved Phase 3,Phase 2 58-05-9 6006 143
12
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 241903 13342
13
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
14
Methotrexate Approved Phase 3,Phase 2,Phase 1 59-05-2, 1959-05-2 126941
15
Aminolevulinic acid Approved Phase 3 106-60-5 137
16
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
17
Gefitinib Approved, Investigational Phase 3,Phase 2 184475-35-2 123631
18
Pembrolizumab Approved Phase 3,Phase 2,Phase 1 1374853-91-4
19
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
20
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
21
Cephalexin Approved, Investigational, Vet_approved Phase 3 15686-71-2 27447
22
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
24
Niacin Approved, Investigational, Nutraceutical Phase 3,Phase 2 59-67-6 938
25
Ornithine Approved, Nutraceutical Phase 3 3184-13-2, 70-26-8 6262
26
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 388082-78-8, 231277-92-2 208908 9941095
27 Tocotrienol Investigational Phase 3 6829-55-6
28
BCG vaccine Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
29
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
30
Levulinic acid Experimental Phase 3 123-76-2 11579
31
Fenretinide Investigational Phase 3 65646-68-6
32 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
33 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
34 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
35 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
36 Immunologic Factors Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
37 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
38 Liposomal amphotericin B Phase 2, Phase 3
39 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1
40 Tocopherols Phase 3
41 Micronutrients Phase 3,Phase 2,Early Phase 1
42 Tocotrienols Phase 3
43 Vitamins Phase 3,Phase 2
44 Antioxidants Phase 3
45 Trace Elements Phase 3,Phase 2,Early Phase 1
46 Protective Agents Phase 3
47 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
48 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
49 Antimitotic Agents Phase 3,Phase 2,Phase 1
50 Vitamin B Complex Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 205)
# Name Status NCT ID Phase Drugs
1 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3 gemcitabine
2 A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
3 Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer Unknown status NCT00553345 Phase 3 selenium;vitamin E
4 Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer Unknown status NCT00553124 Phase 3 selenium;vitamin E
5 Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Unknown status NCT00003725 Phase 3 valrubicin
6 Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
7 Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium Completed NCT00028756 Phase 3 doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin
8 Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer Completed NCT00867347 Phase 3
9 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
10 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00014534 Phase 3 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
11 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
12 High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer Completed NCT00003623 Phase 3
13 Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Completed NCT01668459 Phase 2, Phase 3 Cabazitaxel
14 Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer Completed NCT00002490 Phase 3 mitomycin C
15 Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer Completed NCT00729287 Phase 3
16 Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer Completed NCT00004154 Phase 3 Fenretinide
17 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
18 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Completed NCT00445601 Phase 3 gemcitabine hydrochloride
19 Eflornithine in Treating Patients With Bladder Cancer Completed NCT00003814 Phase 3 eflornithine
20 Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer Completed NCT00033436 Phase 3 carbogen
21 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
22 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
23 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
24 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
25 Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer Recruiting NCT03244384 Phase 3
26 S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Recruiting NCT03091660 Phase 3
27 Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer Recruiting NCT01812369 Phase 3 GEMCITABINE CISPLATINE;METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF
28 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
29 Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Not yet recruiting NCT03775265 Phase 3 Atezolizumab;Cisplatin;Fluorouracil;Gemcitabine;Mitomycin
30 S9809, Ciprofloxacin Compared With Cephalexin in Treating Patients With Bladder Cancer Terminated NCT00003824 Phase 3 cephalexin;Ciprofloxacin
31 BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer Terminated NCT00352079 Phase 3 gefitinib
32 Instillation of Gemcitabine in Patients With Superficial Bladder Cancer Terminated NCT00191477 Phase 3 Gemcitabine;Placebo
33 Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
34 4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer Terminated NCT00005047 Phase 3 cisplatin;doxorubicin hydrochloride;methotrexate;vinblastine
35 Chemotherapy With or Without Surgery in Treating Patients With Bladder Cancer Terminated NCT00042887 Phase 3 mitomycin C
36 Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder Unknown status NCT01222676 Phase 2 cisplatin;gemcitabine hydrochloride;sorafenib tosylate
37 PF-03446962 in Relapsed or Refractory Urothelial Cancer Unknown status NCT01620970 Phase 2 PF03446962
38 Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder Unknown status NCT00694915 Phase 2
39 Alisertib in Chemotherapy-pretreated Urothelial Cancer Unknown status NCT02109328 Phase 2 Alisertib;Paclitaxel;Placebo
40 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
41 Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer Unknown status NCT00006118 Phase 2 cisplatin;gemcitabine hydrochloride;paclitaxel
42 Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer Unknown status NCT01196403 Phase 2
43 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer Unknown status NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
44 Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer Unknown status NCT01118039 Phase 2 sunitinib malate
45 Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer Unknown status NCT00005958 Phase 2 docetaxel;gemcitabine hydrochloride
46 Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder Completed NCT00343356 Phase 2 Trement
47 Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder Completed NCT00963859 Phase 2
48 Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer Completed NCT01118351 Phase 2 sunitinib malate
49 Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma Completed NCT01282463 Phase 2 Docetaxel
50 Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer Completed NCT01824329 Phase 2

Search NIH Clinical Center for Bladder Urothelial Carcinoma

Sources

Genetic Tests for Bladder Urothelial Carcinoma

About this section

Genetic tests related to Bladder Urothelial Carcinoma:

# Genetic test Affiliating Genes
1 Transitional Cell Carcinoma of the Bladder 29
Sources

Anatomical Context for Bladder Urothelial Carcinoma

About this section

MalaCards organs/tissues related to Bladder Urothelial Carcinoma:

41
Prostate, Lymph Node, Testes, Lung, Brain, Kidney, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Urothelial Carcinoma:

19
The Lining Of The Bladder
Sources

Publications for Bladder Urothelial Carcinoma

About this section

Articles related to Bladder Urothelial Carcinoma:

(show top 50) (show all 1047)
# Title Authors Year
1
A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors? ( 29130135 )
2018
2
Quantitative proteomic analysis identifies AHNAK as a novel candidate biomarker for bladder urothelial carcinoma diagnosis by liquid-based cytology. ( 29950347 )
2018
3
RIPK4 promotes bladder urothelial carcinoma cell aggressiveness by upregulating VEGF-A through the NF-I_B pathway. ( 29867225 )
2018
4
Nkx2.8 inhibits epithelial-mesenchymal transition in bladder urothelial carcinoma via transcriptional repression of Twist1. ( 29311157 )
2018
5
Overexpression of high mobility group box 1 contributes to progressive clinicopathological features and poor prognosis of human bladder urothelial carcinoma. ( 29695918 )
2018
6
Knockdown of fibrous sheath interacting protein 1 expression reduces bladder urothelial carcinoma cell proliferation and induces apoptosis via inhibition of the PI3K/AKT pathway. ( 29670371 )
2018
7
SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival. ( 29662193 )
2018
8
Long non-coding RNA CDKN2B antisense RNA 1 gene inhibits Gemcitabine sensitivity in bladder urothelial carcinoma. ( 29937935 )
2018
9
Upregulation of Arp2 expression is associated with the prognosis and prediction of lymph node metastasis in bladder urothelial carcinoma. ( 29593429 )
2018
10
Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis. ( 29391889 )
2018
11
Under-stage and Overlook of Peritoneal Spread from Bladder Urothelial Carcinoma. ( 29936478 )
2018
12
Combined use of urinary Survivin detection and liquid-based cytology for the early diagnosis of bladder urothelial carcinoma. ( 29725469 )
2018
13
Expression of PLAGL2 in bladder urothelial carcinoma and its relationship to lymph node metastasis and survival. ( 29662235 )
2018
14
LINE-1 ORF1 Protein Is Up-regulated by Reactive Oxygen Species and Associated with Bladder Urothelial Carcinoma Progression. ( 29496693 )
2018
15
Squamous differentiation in pT1 bladder urothelial carcinoma predicts poor response for intravesical chemotherapy. ( 29416608 )
2018
16
Clinical and cytopathological factors affecting the cellularity of urinary cell blocks and the implication for the diagnosis and follow-up of the urinary bladder urothelial carcinoma. ( 29873845 )
2018
17
Functional Genomics Profiling of Bladder Urothelial Carcinoma MicroRNAome as a Potential Biomarker. ( 29544183 )
2018
18
Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy. ( 29084921 )
2018
19
miR-99a-5p acts as tumor suppressor via targeting to mTOR and enhances RAD001-induced apoptosis in human urinary bladder urothelial carcinoma cells. ( 29379304 )
2018
20
Proteomic Identification of the Galectin-1-Involved Molecular Pathways in Urinary Bladder Urothelial Carcinoma. ( 29671787 )
2018
21
Deciphering the Molecular Mechanism Underlying the Inhibitory Efficacy of Taiwanese Local Pomegranate Peels against Urinary Bladder Urothelial Carcinoma. ( 29702555 )
2018
22
Fibroblasts from pBOO promote tumorigenesis by secreting TGFbeta1 to induce EMT in bladder urothelial carcinoma cells. ( 29934361 )
2018
23
Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. ( 30017405 )
2018
24
The effect of marital status on the survival of patients with bladder urothelial carcinoma: A SEER database analysis. ( 30024509 )
2018
25
CAD/POLD2 gene expression is associated with poor overall survival and chemoresistance in bladder urothelial carcinoma. ( 30038717 )
2018
26
Prognostic Signature of Alternative Splicing Events in Bladder Urothelial Carcinoma Based on Spliceseq Data from 317 Cases. ( 30048970 )
2018
27
TRIM65 supports bladder urothelial carcinoma cell aggressiveness by promoting ANXA2 ubiquitination and degradation. ( 30075204 )
2018
28
Expression pattern of p53-binding protein 1 as a new molecular indicator of genomic instability in bladder urothelial carcinoma. ( 30341375 )
2018
29
Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma. ( 30352907 )
2018
30
RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update. ( 30359990 )
2018
31
Long non-coding RNA MEG3 suppresses the development of bladder urothelial carcinoma by regulating miR-96 and TPM1. ( 30461333 )
2018
32
Clinical and molecular characteristics of bladder urothelial carcinoma subtypes. ( 30548659 )
2018
33
Enterovesical Fistula Secondary to Transitional Cell Carcinoma of the Bladder. ( 30474067 )
2018
34
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). ( 30279015 )
2018
35
Solute carrier family 12 member 5 promotes tumor invasion/metastasis of bladder urothelial carcinoma by enhancing NF-I_B/MMP-7 signaling pathway. ( 28333147 )
2017
36
Identification and functional analysis of risk-related microRNAs for the prognosis of patients with bladder urothelial carcinoma. ( 29344166 )
2017
37
Ki-67 and Cell Cycle Regulators p53, p63 and cyclinD1 as Prognostic Markers for Recurrence/ Progression of Bladder Urothelial Carcinoma. ( 28488128 )
2017
38
Bladder urothelial carcinoma extending to rectal mucosa and presenting with rectal bleeding. ( 28690772 )
2017
39
The expression and clinical significance of ZBTB7 in transitional cell carcinoma of the bladder. ( 29085492 )
2017
40
Transcriptome sequencing identifies ANLN as a promising prognostic biomarker in bladder urothelial carcinoma. ( 28600503 )
2017
41
Galectin-9 as a prognostic and predictive biomarker in bladder urothelial carcinoma. ( 28347658 )
2017
42
Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder. ( 28417194 )
2017
43
Knockdown of long non-coding RNA Taurine Up-Regulated 1 inhibited doxorubicin resistance of bladder urothelial carcinoma via Wnt/I^-catenin pathway. ( 29179467 )
2017
44
Association Between Human Papillomavirus and Transitional Cell Carcinoma of the Bladder. ( 29101759 )
2017
45
The prognostic value of preoperative serum albumin-globulin ratio for high-grade bladder urothelial carcinoma treated with radical cystectomy: A propensity score-matched analysis. ( 29237914 )
2017
46
LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma. ( 28969069 )
2017
47
Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study. ( 28291636 )
2017
48
Vaginal metastasis of bladder urothelial carcinoma: Description of a case and revision of literature. ( 28679193 )
2017
49
Impact of preoperative diagnostic TURBT on progression-free survival in patients with pathological high-grade, stage T3/T4 bladder urothelial carcinoma. ( 29179514 )
2017
50
Mex3a expression and survival analysis of bladder urothelial carcinoma. ( 28903380 )
2017
Sources

Variations for Bladder Urothelial Carcinoma

About this section

ClinVar genetic disease variations for Bladder Urothelial Carcinoma:

6 (show top 50) (show all 555)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 GRCh38 Chromosome 17, 7674221: 7674221
3 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
4 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
5 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
6 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 GRCh38 Chromosome 17, 7674238: 7674238
7 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
8 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 GRCh38 Chromosome 17, 7674229: 7674229
9 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
10 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
11 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
12 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Likely pathogenic rs121912657 GRCh38 Chromosome 17, 7673806: 7673806
13 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
14 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
15 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
16 TP53 NM_000546.5(TP53): c.844C> T (p.Arg282Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28934574 GRCh38 Chromosome 17, 7673776: 7673776
17 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
18 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 GRCh38 Chromosome 17, 7674230: 7674230
19 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
20 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
21 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh37 Chromosome 17, 7577099: 7577099
22 TP53 NM_000546.5(TP53): c.839G> C (p.Arg280Thr) single nucleotide variant Uncertain significance rs121912660 GRCh38 Chromosome 17, 7673781: 7673781
23 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
24 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
25 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
26 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh38 Chromosome 17, 7675161: 7675161
27 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
28 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 GRCh38 Chromosome 17, 7674872: 7674872
29 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
30 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
31 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
32 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 GRCh38 Chromosome 11, 534288: 534288
33 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
34 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh38 Chromosome 11, 534286: 534286
35 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
36 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 GRCh38 Chromosome 11, 534289: 534289
37 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
38 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
39 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
40 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 GRCh38 Chromosome 3, 179234297: 179234297
41 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
42 PIK3CA NM_006218.3(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
43 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
44 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
45 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
46 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
47 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
48 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh37 Chromosome 3, 178936094: 178936094
49 PIK3CA NM_006218.3(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 GRCh38 Chromosome 3, 179218306: 179218306
50 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
Sources

Expression for Bladder Urothelial Carcinoma

About this section
Search GEO for disease gene expression data for Bladder Urothelial Carcinoma.
Sources

Pathways for Bladder Urothelial Carcinoma

About this section

Pathways related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 202)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 14.21 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
2
ERK Signaling 64
Show member pathways
 14.03 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
3
Apoptotic Pathways in Synovial Fibroblasts 64
Show member pathways
 14.01 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
4
HIV Life Cycle 66
Show member pathways
 13.91 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
5
GPCR Pathway 64
Show member pathways
 13.9 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
6
PEDF Induced Signaling 64
Show member pathways
 13.86 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
7
Activation of cAMP-Dependent PKA 64
Show member pathways
 13.75 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
8
TGF-Beta Pathway 64
Show member pathways
 13.74 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
9
Developmental Biology 66
Show member pathways
 13.71 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
10
Class I MHC mediated antigen processing and presentation 66
Show member pathways
 13.64 AKT1 ERBB2 FGFR1 FGFR3 HRAS KRAS
11
Akt Signaling 64
Show member pathways
 13.58 AKT1 ERBB2 FGFR1 FGFR3 HRAS KRAS
12
Integrin Pathway 64
Show member pathways
 13.57 AKT1 BRAF CTNNB1 HRAS KRAS MAP2K1
13
Cytokine Signaling in Immune system 66
Show member pathways
 13.57 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
14
CREB Pathway 64
Show member pathways
 13.51 AKT1 ERBB2 FGFR1 FGFR3 HRAS KRAS
15
Nanog in Mammalian ESC Pluripotency 64
Show member pathways
 13.5 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
16
PAK Pathway 64
Show member pathways
 13.49 AKT1 CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
17
IL-2 Pathway 64
Show member pathways
 13.4 AKT1 BRAF ERBB2 HRAS KRAS MAP2K1
18
Phospholipase-C Pathway 64
Show member pathways
 13.29 AKT1 BRAF FGFR1 FGFR3 HRAS KRAS
19
Human cytomegalovirus infection 37
Show member pathways
 13.27 AKT1 CTNNB1 HRAS KRAS MAP2K1 NRAS
20
PI3K/AKT activation 66
Show member pathways
 13.25 AKT1 ERBB2 FGFR1 FGFR3 PIK3CA TP53
21
p70S6K Signaling 64
Show member pathways
 13.24 AKT1 FGFR1 FGFR3 HRAS KRAS MAP2K1
22
G-Beta Gamma Signaling 64
Show member pathways
 13.23 AKT1 BRAF CTNNB1 HRAS KRAS MAP2K1
23
fMLP Pathway 64
Show member pathways
 13.23 AKT1 BRAF CTNNB1 HRAS KRAS MAP2K1
24
PI3K-Akt signaling pathway 37
Show member pathways
 13.22 AKT1 CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
25
Circadian entrainment 37
Show member pathways
 13.18 AKT1 HRAS KRAS MAP2K1 NRAS PIK3CA
26
TNFR1 Pathway 64
Show member pathways
 13.17 AKT1 CTNNB1 HRAS KRAS MAP2K1 NRAS
27
Development Angiotensin activation of ERK 22
Show member pathways
 13.14 AKT1 BRAF HRAS KRAS MAP2K1 NRAS
28
Sertoli-Sertoli Cell Junction Dynamics 64
Show member pathways
 13.13 AKT1 BRAF CTNNB1 HRAS KRAS MAP2K1
29
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.13 AKT1 BRAF ERBB2 HRAS KRAS MAP2K1
30
Focal Adhesion 1 37
Show member pathways
 13.12 AKT1 BRAF CTNNB1 ERBB2 HRAS KRAS
31
CCR5 Pathway in Macrophages 64
Show member pathways
 13.09 AKT1 BRAF HRAS KRAS MAP2K1 NRAS
32
TCR Signaling (Qiagen) 64
Show member pathways
 13.08 AKT1 HRAS KRAS MAP2K1 NRAS TP53
33
NFAT and Cardiac Hypertrophy 64
Show member pathways
 13.08 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
34
Endometrial cancer 37
Show member pathways
 13.07 AKT1 BRAF CTNNB1 ERBB2 FGFR1 HRAS
35
Downstream signaling of activated FGFR2 66
Show member pathways
 13.03 FGFR1 FGFR3 HRAS KRAS NRAS PIK3CA
36
Apoptosis Modulation and Signaling 1
Show member pathways
 13.03 AKT1 HRAS KRAS MAP2K1 NRAS PIK3CA
37
Beta-Adrenergic Signaling 64
Show member pathways
 13.03 AKT1 BRAF CTNNB1 HRAS KRAS MAP2K1
38
MAPK-Erk Pathway 67
Show member pathways
 13.01 BRAF HRAS KRAS MAP2K1 NRAS PIK3CA
39
MAPK signaling pathway 37 1
12.99 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
40
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 65
Show member pathways
 12.97 AKT1 BRAF HRAS KRAS MAP2K1 PIK3CA
41
Ras signaling pathway 37
Show member pathways
 12.96 AKT1 BRAF CTNNB1 FGFR1 FGFR3 HRAS
42
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.95 AKT1 ERBB2 FGFR1 FGFR3 HRAS KRAS
43
Glioma 37
Show member pathways
 12.95 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
44
Development HGF signaling pathway 22
Show member pathways
 12.94 AKT1 BRAF CTNNB1 ERBB2 HRAS KRAS
45
Vascular smooth muscle contraction 37
Show member pathways
 12.92 AKT1 BRAF HRAS KRAS MAP2K1 NRAS
46
4-1BB Pathway 64
Show member pathways
 12.91 AKT1 BRAF HRAS KRAS MAP2K1 NRAS
47
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.9 AKT1 CTNNB1 HRAS KRAS MAP2K1 NRAS
48
Pathways in cancer 37
12.9 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
49
G-AlphaQ Signaling 64
Show member pathways
 12.87 AKT1 BRAF HRAS KRAS MAP2K1 NRAS
50
Regulation of actin cytoskeleton 1 37
12.86 BRAF FGFR1 FGFR3 HRAS KRAS MAP2K1
Sources

GO Terms for Bladder Urothelial Carcinoma

About this section

Biological processes related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.92 AKT1 ERBB2 HRAS KRAS
2 negative regulation of apoptotic process GO:0043066 9.91 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
3 protein autophosphorylation GO:0046777 9.9 AKT1 ERBB2 FGFR1 FGFR3
4 positive regulation of protein kinase B signaling GO:0051897 9.89 ERBB2 FGFR1 FGFR3 PIK3CA
5 negative regulation of gene expression GO:0010629 9.89 AKT1 CTNNB1 FGFR1 HRAS MAP2K1
6 negative regulation of neuron apoptotic process GO:0043524 9.86 BRAF HRAS KRAS PIK3CA
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 AKT1 BRAF PIK3CA
8 cellular response to hypoxia GO:0071456 9.84 AKT1 MALAT1 NFE2L2 TP53
9 cellular response to drug GO:0035690 9.83 BRAF NFE2L2 TP53
10 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.82 HRAS KRAS NRAS
11 phosphatidylinositol phosphorylation GO:0046854 9.81 ERBB2 FGFR1 FGFR3 PIK3CA
12 cellular response to growth factor stimulus GO:0071363 9.8 AKT1 CTNNB1 ERBB2
13 peptidyl-tyrosine phosphorylation GO:0018108 9.8 BRAF ERBB2 FGFR1 FGFR3 MAP2K1
14 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.79 FGFR1 FGFR3 PIK3CA
15 positive regulation of blood vessel endothelial cell migration GO:0043536 9.76 AKT1 FGFR1 NFE2L2
16 thymus development GO:0048538 9.75 BRAF CTNNB1 MAP2K1
17 Ras protein signal transduction GO:0007265 9.73 HRAS KRAS NRAS TP53
18 phosphatidylinositol 3-kinase signaling GO:0014065 9.7 AKT1 ERBB2 PIK3CA
19 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.67 AKT1 NFE2L2
20 positive regulation of phospholipase C activity GO:0010863 9.67 FGFR1 HRAS
21 anoikis GO:0043276 9.66 AKT1 PIK3CA
22 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.66 MAP2K1 TP53
23 lung-associated mesenchyme development GO:0060484 9.65 CTNNB1 FGFR1
24 positive regulation of phospholipase activity GO:0010518 9.65 FGFR1 FGFR3
25 positive regulation of MAPK cascade GO:0043410 9.65 CTNNB1 ERBB2 FGFR1 FGFR3 HRAS
26 regulation of axon regeneration GO:0048679 9.64 BRAF MAP2K1
27 response to isolation stress GO:0035900 9.63 HRAS KRAS
28 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.63 BRAF ERBB2 FGFR1 FGFR3 HRAS MAP2K1
29 trachea formation GO:0060440 9.62 CTNNB1 MAP2K1
30 positive regulation of MAP kinase activity GO:0043406 9.62 ERBB2 FGFR1 HRAS KRAS
31 positive regulation of gene expression GO:0010628 9.61 AKT1 BRAF CTNNB1 ERBB2 HRAS KRAS
32 MAPK cascade GO:0000165 9.23 BRAF ERBB2 FGFR1 FGFR3 HRAS KRAS
33 cell differentiation GO:0030154 10.11 AKT1 BRAF CTNNB1 ERBB2 FGFR1 FGFR3
34 positive regulation of cell proliferation GO:0008284 10.02 AKT1 CTNNB1 FGFR1 FGFR3 HRAS KRAS
35 phosphorylation GO:0016310 10.02 AKT1 BRAF ERBB2 FGFR1 FGFR3 MAP2K1
36 cell proliferation GO:0008283 10 AKT1 CTNNB1 ERBB2 HRAS TP53
37 protein phosphorylation GO:0006468 10 AKT1 BRAF ERBB2 FGFR1 FGFR3 MAP2K1

Molecular functions related to Bladder Urothelial Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein C-terminus binding GO:0008022 9.8 CTNNB1 ERBB2 HRAS MAP2K1
2 protein kinase activity GO:0004672 9.8 AKT1 BRAF ERBB2 FGFR1 FGFR3 MAP2K1
3 kinase activity GO:0016301 9.8 AKT1 BRAF ERBB2 FGFR1 FGFR3 MAP2K1
4 protein phosphatase binding GO:0019903 9.69 CTNNB1 ERBB2 TP53
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.65 ERBB2 FGFR1 FGFR3
6 1-phosphatidylinositol-3-kinase activity GO:0016303 9.54 FGFR1 FGFR3 PIK3CA
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.46 ERBB2 FGFR1 FGFR3 PIK3CA
8 fibroblast growth factor-activated receptor activity GO:0005007 9.4 FGFR1 FGFR3
9 protein tyrosine kinase activity GO:0004713 9.35 BRAF ERBB2 FGFR1 FGFR3 MAP2K1
10 nucleotide binding GO:0000166 9.28 AKT1 BRAF ERBB2 FGFR1 FGFR3 HRAS
11 ATP binding GO:0005524 10.03 AKT1 BRAF ERBB2 FGFR1 FGFR3 MAP2K1
12 identical protein binding GO:0042802 10 AKT1 BRAF ERBB2 FGFR1 FGFR3 IDH1
Sources

Sources for Bladder Urothelial Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....